Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
10X Genomics Sweden AB is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This singular focus suggests that the company is currently prioritizing a specific technical advancement or a single patent application.
AMY M BUNKER is the busiest examiner for this portfolio, with 1 busiest examiner pending action currently on her docket. As the only examiner involved in the company's active prosecution, her specific feedback and examination style are the primary factors in the application's progress. The use of 1 distinct art unit indicates that the technical scope of the pending Biotechnology & Pharmaceuticals work is highly concentrated.
The presence of only 1 pending office action allows the legal team to dedicate its full attention to a single set of examiner concerns. There is no need to coordinate across multiple examiners or art units at this time. This active matter represents the entirety of the company's current active engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNKER, AMY M | 1 | 29.1% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672671 | METHODS OF DETECTING ANALYTES | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672671 | METHODS OF DETECTING ANALYTES | BUNKER, AMY M | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18672671 | METHODS OF DETECTING ANALYTES | BUNKER, AMY M | 1684 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial10X Genomics Sweden AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amy M Bunker has the most, with 1 of 10X Genomics Sweden AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
